New drug SKB105 tested in advanced cancer patients who have no other options
NCT ID NCT07380386
First seen Feb 02, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This study tests a new drug, SKB105, in 256 adults with advanced solid tumors that have not responded to standard treatments or are not eligible for them. The trial has three stages to find the best dose and see if the drug shrinks tumors or slows cancer growth. The main goals are safety and whether tumors shrink, with a focus on people aged 18 to 75.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Email: •••••@•••••
-
Shangahi Chest Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.